A phase II clinical trial of frameless, fractionated stereotactic radiation therapy for brain metastases.
JNCI Cancer Spectr
; 7(6)2023 Oct 31.
Article
em En
| MEDLINE
| ID: mdl-37944053
ABSTRACT
Stereotactic radiation therapy yields high rates of local control for brain metastases, but patients in rural or suburban areas face geographic and socioeconomic barriers to its access. We conducted a phase II clinical trial of frameless, fractionated stereotactic radiation therapy for brain metastases in an integrated academic satellite network for patients 18 years of age or older with 4 or fewer brain metastases. Dose was based on gross tumor volume less than 3.0 cm, 27 Gy in 3 fractions and 3.0 to 3.9 cm, 30 Gy in 5 fractions. Median follow-up was 10 months for 73 evaluable patients, with a median age of 68 years. Median intracranial progression-free survival was 7.1 months (95% confidence interval = 5.3 to not reached), and median survival was 7.2 months (95% confidence interval = 5.4 to not reached); there were no serious adverse events. Outcomes of this trial compare favorably with contemporary trials, and this treatment strategy provides opportunities to expand stereotactic radiation therapy access to underserved populations.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Encefálicas
/
Radiocirurgia
Limite:
Adolescent
/
Adult
/
Aged
/
Humans
Idioma:
En
Revista:
JNCI Cancer Spectr
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
Estados Unidos